overhang reiter uw
believ primari debat around appropri medium-term growth rate
busi reflect year surprisingli volatil water
featur three guidanc revis lower end line organ
growth lower bar water remain bullish appropri
growth rate busi mid-singl digit organ growth
attribut macro factor medium-term optim driven popul
growth demograph emerg market expans said skeptic
driven fact tool peer abl demonstr stronger growth
remain cautiou leadership posit liquid chromatographi
exposur weaker
small molecul manufactur
biopharma sale end market flat y/i ex-fx
year also meaning exposur industri end market
sale condit remain weak year-end ex-fx
recommend invest aggress
tuck grow variou end market pressur compani
remain bullish prospect sever new platform mass spectrometri
said expect contribut growth appear modest water
 invest lag peer percentag product revenu
disappoint appear held back spend
also exhaust major compani capit deploy flexibl
buyback sinc anoth expect retrospect
given top line under-perform think capit alloc could better
alloc toward tuck-in potenti bioproduct target would expens
though also compet strateg acquir find
look forecast ex-fx growth given mute
outlook remain valuat sensit share trade premium tool
peer reiter underweight rate lower pt
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
idc link barclay live interact chart
underweight specialti provid
life scienc tool market leadership posit
liquid chromatographi thermal analysi
instrument current macro environ
cautiou around exposur industri
custom sale also see risk around
new invest lc exposur small
biopharma remain area strength higher
consum margin drive upsid ebitda
expect upsid ebitda
million yield upsid case
fund biotech pressur capit invest
life scienc tool drive downsid ebitda
estim downsid ebitda
million yield downsid case
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
primari debat around appropri medium-term growth rate
busi reflect year surprisingli volatil water featur three
guidanc revis lower end line organ growth
lower bar water remain bullish appropri growth rate
busi mid-singl digit organ growth attribut macro
factor medium term optim driven popul growth demograph
emerg market expans said skeptic driven fact tool
peer abl demonstr stronger growth remain cautiou water
leadership posit liquid chromatographi exposur weaker invest trend
small molecul manufactur biopharma sale end market flat y/i
ex-fx year also meaning exposur
industri end market sale condit remain weak year-end
recommend invest aggress tuck
 grow variou end market pressur compani remain bullish
prospect sever new platform mass spectrometri said
expect contribut growth appear modest invest
lag peer percentag product revenu spend peer level
averag disappoint appear held back
spend face top line pressur ex-fx quarter
sg also came surprisingli expect water also
exhaust major compani capit deploy flexibl buyback
sinc anoth expect coupl cost
reduct buy-back help preserv ep growth provid
valuat support compani stock retrospect given top
under-perform think capit alloc could better alloc toward
tuck-in biopharma sponsor put increment invest behind larg
molecul therapi signific driver growth bioproduct
industri unfortun valuat bioproduct asset also increas
time potenti target would expens would also compet
strateg acquir find better synergi
look forecast ex-fx growth given mute outlook
remain valuat sensit share trade premium life scienc tool
peer reiter underweight rate lower pt
reiter underweight rate lower price target
pt repres adj ebitda forecast prior pt
repres prior adj ebitda forecast
instrument sale remain weak cautiou could
lead soft recur revenu growth head model post
ex-fx declin instrument sale compar growth
specif weak
result ex-fx attribut soft within lc instrument expect
instrument sale remain modest near term given macro outlook industri
custom well continu consolid small molecul manufactur
capit sale
fundament concern recur revenu could continu moder
due recent weak
chromatographi instrument placement uplc/hplc system yield recur
sale chromatographi column chemistri believ lower instrument sale led
lag impact recur sale roughli one year chemistri sale recent
declin organ growth
forecast organ growth chemistri sale
water segment organ growth product categori
stack recent result mass spectrometri chromatographi water
notabl laggard versu peer water water segment post averag
organ growth sinc begin compar almost growth
thermo fisher period growth agil across lsag acg
organ growth mass spec chromatographi busi
note fiscal year quarter compani
water recent introduc two new high end instrument compani expect
contribut growth new cyclic im synapt xs platform
began ship late water also introduc compani new bioaccord
platform design robust mass spectrometri base approach qa/qc larg
ceo chri oconnel commentari mass spec launch earn
market dynam asid remain sharpli focus core growth strategi organ innov excit
signific uptick meaning new product launch pleas market develop
activ date particularli encourag increas contribut new product notabl
bioaccord cyclic im two new tandem quad mass spectromet contribut meaning
growth quarter expect new product contribut continu ramp remain
excit technolog roadmap believ front end major new product cycl
also durabl improv product therefor sustain new product cadenc
capit deploy strategi larg favor buy-back would
recommend priorit resourc toward acquisit invest
strateg expand exposur stronger end market given water relationship
pharma biotech sponsor compani right compet win larg
molecul applic compani good start invest behind
bioaccord mass spectrometri analyz design multi-attribut monitor along
bioproduct workflow said believ increas invest need
strengthen increment growth steadili increas compani budget
year rel spend percentag product revenu lag peer
growth
analyt instrument mm product rev
note thermo fisher ai analyt instrument segment
 mm product sale
one limit factor enter bioproduct market
recent transact price continu move higher view reflect
diverg drug develop trend small larg molecul anoth issu
compani compet consolid best bioproduct
target given scale lead bioproduct compani believ would
difficult match potenti synergi target would either limit abil water
 total revenu product fisher product sale barclay corp
match competitor price would limit potenti deal accret
interestingli updat term credit agreement februari
allow increas leverag materi acquisit
notabl compani amend senior unsecur note agreement allow
compani elect increas permit leverag ratio
period three consecut quarter period time leverag ratio
exce interest payabl senior unsecur note shall increas
note transact inform factual
water commentari earn
ceo chri connel past year strengthen intern capabl built robust acquisit
minor invest pipelin last month announc acquisit andrew allianc broaden
technolog portfolio includ advanc robot softwar posit impact custom workflow across
pharmaceut life scienc materi scienc market
cfo sherri buck look go varieti factor look prioriti
busi standpoint perform et cetera realli look repurchas year million
would put us base upon guid gave today low leverag ratio factor could increas us
toward kind near-term goal could opportun
earn introduc revenu line model ep
guidanc prior estim revenu compani forecast constant
currenc growth fx expect roughli neutral less headwind drive
total revenu year gross margin expect
oper margin expect guidanc assum million repurchas
includ million would bring compani weight
averag share count million tax anticip non-gaap tax rate
also initi ep guidanc rang repres
growth y/i foreign exchang expect headwind ep
andrew allianc acquisit modestli dilut
guid toward constant currenc revenu growth less
headwind fx impli total revenu growth ep expect
rang fx expect headwind ep
date announcedacquirertargetd evttm fisherlif part fisheradvanc scientif corpor technolog fisherfiness part broader life scienc price net tax barclay corp
guidanc
revenu million line forecast constant
currenc growth line expect model midpoint
manag guidanc revenu repres growth y/i ex-fx
total growth fx headwind compar compani guidanc
million embed organ growth fx headwind
underli growth across product segment mix notabl instrument sale
remain weak organ growth assum includ declin
water segment instrument vs ta segment ex-fx water
chemistri sale steadi organ growth though compani benefit
extra sell day typic help recur revenu instrument overal
y/i ex-fx estim water instrument vs ta instrument ex-fx
recur revenu grew y/i ex-fx includ growth servic
end market perspect biopharma full-year sale end market
deliv ex-fx deceler compani note weak
due industri market china continu weak small molecul pharma
water point growth larg molecul pharma biomed research applic
new product offer industri full-year sale end market declin y/i
deceler growth water point strength food test
market off-set weak materi character water identifi difficult
industri macro environ headwind segment govern academ
full-year sale end market grew ex-fx y/i compar organ
declin growth water note strong growth biomed
research applic pharma research driven impact new technolog
particularli europ
growth adj day barclay corp
growth across geograph end market mix asia flat growth driven
modest declin china due difficult comp pharma partial off-set food
improv food market water note second phase program
play expect third phase underway water also note chemistri
see strong demand expect continu program support gener
prescript volum europ revenu solid pharmaceut growth
result solid year-end spend certain larg pharma custom continu
strength academ off-set partial declin industri america sale
declin us flat polit uncertainti note headwind
mexico brazil result caus strength larg pharma food
biomed research off-set weak small molecul materi scienc clinic
water geograph divers rev
water revenu breakdown end market
tool average includ agil thermo fisher
revenu grew organ though declin ta
water divis revenu growth ex-fx y/i water divis
revenu million came million expect million
improv y/i organ basi revenu increas y/i
estim chemistri revenu growth ex-fx better organ
expect off-set instrument revenu declin ex-
fx in-lin expect ex-fx servic revenu increas organ
compar model currenc headwind segment revenu
quarter versu forecast
ta instrument divis revenu declin ex-fx y/i ta instrument
revenu million came million estim declin
organ y/i versu forecast organ currenc headwind
quarter versu estim headwind
water revenu segment million
non-gaap ep increas y/i driven better-than-expect
interest expens tax rate estim tax rate came
forecast ad quarterli result note ep came
manag guidanc adjust ep came estim
water non-gaap ep growth
gross margin came expect impact
fx lower fix cost absorpt mix gross margin y/i
full year gross margin miss full-year guidanc
water gross margin annual growth
sg ex-stock comp expens declin y/i revenu
 expens total revenu y/i model
rel steadi expenditur compani continu invest intern growth
water adjust sg trend
adjust oper incom million declin y/i though came
modestli forecast oper margin declin y/i
estim mix oper expens drove oper incom beat
gross margin expect off-set opex percentag
revenu come estim ex-stock comp
water ebit margin annual growth
deliv million cffo forecast work
capit similar estim vs model compani
activ share repurchas repurchas share model
anoth begin announc billion
share repurchas author compani expect net leverag ratio
end
water use oper million
 mm except ep reportedincom growth profit ebitda ebit debt pre-tax pre-tax tax net adj net researchprior yearprior quarter barclay corp
estestestestestestestestincom statement growth growth growth growth growth growth y/i growth y/i organ adj growth product product product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth growth y/i administr growth growth y/i base sg stock base oper growth growth y/i ebitda growth acquir intang oper incom ebit growth debt invest pre-tax pre-tax growth benefit incom tax net net growth adj adj net barclay corp
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
